mercaptopurine and Encephalomyelitis

mercaptopurine has been researched along with Encephalomyelitis* in 7 studies

Other Studies

7 other study(ies) available for mercaptopurine and Encephalomyelitis

ArticleYear
INTRODUCTORY REMARKS: SUPPRESSION OF DEMYELINATING DISEASE.
    Annals of the New York Academy of Sciences, 1965, Mar-31, Volume: 122

    Topics: Demyelinating Diseases; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Immunosuppressive Agents; Mercaptopurine; Methotrexate; Methylprednisolone; Pharmacology

1965
CURRENT STUDIES ON THE EFFECT ANTIMETABOLITES IN NEPHROSIS, OTHER NON-NEOPLASTIC DISEASES, AND EXPERIMENTAL ANIMALS. COMBINED CLINICAL STAFF CONFERENCE AT THE NATIONAL INSTITUTES OF HEALTH.
    Annals of internal medicine, 1963, Volume: 59

    Topics: Agammaglobulinemia; Alanine Transaminase; Animals; Antimetabolites; Autoimmune Diseases; Clinical Enzyme Tests; Encephalomyelitis; Hepatitis; Hypersensitivity; Lupus Erythematosus, Systemic; Mercaptopurine; National Institutes of Health (U.S.); Nephrosis; Nephrotic Syndrome; Prednisone; Skin Tests; United States

1963
Effects of 6-mercaptopurine on susceptibility of guinea pigs to experimental allergic encephalomyelitis.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1962, Volume: 111

    Topics: Animals; Disease Susceptibility; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Guinea Pigs; Mercaptopurine

1962
Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine.
    The Journal of experimental medicine, 1962, Sep-01, Volume: 116

    1. 6-Mercaptopurine (6-MP) prevents experimental allergic encephalomyelitis (EAE) during the period of drug administration in both rabbits and guinea pigs. The disease is suppressed even when treatment is started as late as the 5th day after antigenic stimulation in guinea pigs and the 12th day in rabbits. 2. After discontinuation of 6-MP treatment, there is a latent period before the disease is noted. The length of this latent period is not modified by the duration of 6-MP treatment. 3. The effect of 6-MP on EAE is not the result of leukopenia, non-specific toxicity and debilitation, anti-inflammatory activity, or mere masking of clinical signs of the disease. It is, rather, the result of 6-MP's specific anti-immunologic activity. 4. The effects of 6-MP on antibody production, delayed hypersensitivity, and EAE are compared. This provides indirect evidence for the importance of circulating antibody in the pathogenesis of EAE. 5. The important considerations in the use of 6-MP are discussed and the possible usefulness of 6-MP in human neurologic diseases is considered.

    Topics: Animals; Antibody Formation; Antigens; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Guinea Pigs; Humans; Hypersensitivity; Mercaptopurine; Rabbits

1962
Studies in the inhibition of experimental allergic encephalomyelitis.
    Archives internationales de pharmacodynamie et de therapie, 1961, Nov-01, Volume: 134

    Topics: Adrenocorticotropic Hormone; Animals; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Mercaptopurine; Salicylates

1961
Prevention of experimental allergic encephalomyelitis with 6-mercaptopurine.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1960, Volume: 103

    Topics: Animals; Biomedical Research; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Mercaptopurine

1960
The metabolism of 6-thioguanine in normal and neoplastic tissues.
    Cancer research, 1958, Volume: 18, Issue:9

    Topics: Encephalomyelitis; Humans; Mercaptopurine; Neoplasms; Thioguanine

1958